Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/2023-504509-36-00
2023-504509-36-00CompletedPhase 4

Bioequivalence study of a proposed biosimilar insulin glargine U300 with Toujeo®

Biocon Sdn. Bhd.1 site in 1 country68 target enrollmentStarted: June 20, 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 4
Status
Completed
Enrollment
68
Locations
1
Study OverviewEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Eligibility Criteria

Ages
18 years to 64 years (18-64 Years)
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Sponsor Class
Pharmaceutical company
Responsible Party
Principal Investigator
Principal Investigator

Sponsor’s Responsible Medical Monitor

Scientific

Biocon Sdn. Bhd.

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 1
A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy Adults
NCT07261371Pfizer64
Active, not recruiting
Not Applicable
西诺氨酯片人体生物等效性试验
CTR2025430856
Active, not recruiting
Not Applicable
螺内酯片在中国健康受试者中空腹状态下随机、开放、单次给药、两制剂、两周期两序列交叉的生物等效性研究1.水肿性疾病：与其他利尿药合用，治疗充血性水肿、肝硬化腹水、肾性水肿等水肿性疾病，其目的在于纠正上述疾病时伴发的继发性醛固酮分泌增多，并对抗其他利尿药的排钾作用。也用于特发性水肿的治疗。 2.高血压：作为治疗高血压的辅助药物。 3.原发性醛固酮增多症：螺内酯可用于此病的诊断和治疗。 4.低血钾症的预防：与噻嗪类利尿药合用，增强利尿效应和预防低血钾症。
CTR2025493132
Completed
Not Applicable
双氯芬酸二乙胺乳胶剂生物等效性研究
CTR2025165448
Not yet recruiting
Not Applicable
Examination of equivalence between biosimilar and original in insulin lisproType 1 and type 2 diabetes
JPRN-UMIN000042016Hamamatsu University School of Medicine30